As of 2024-09-08, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -8.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 324.83 mil USD. TBPH's TTM EBITDA according to its financial statements is -37.22 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.6x - 7.7x | 6.9x |
| Forward P/E multiples | 5.4x - 8.7x | 6.5x |
| Fair Price | (2.92) - (4.47) | (3.73) |
| Upside | -136.5% - -155.8% | -146.5% |
| Date | EV/EBITDA |
| 2024-09-06 | -8.73 |
| 2024-09-05 | -8.94 |
| 2024-09-04 | -8.77 |
| 2024-09-03 | -8.71 |
| 2024-08-30 | -9.04 |
| 2024-08-29 | -8.99 |
| 2024-08-28 | -8.92 |
| 2024-08-27 | -9.21 |
| 2024-08-26 | -8.90 |
| 2024-08-23 | -8.83 |
| 2024-08-22 | -8.73 |
| 2024-08-21 | -8.77 |
| 2024-08-20 | -9.00 |
| 2024-08-19 | -9.21 |
| 2024-08-16 | -8.90 |
| 2024-08-15 | -9.04 |
| 2024-08-14 | -8.95 |
| 2024-08-13 | -9.08 |
| 2024-08-12 | -9.03 |
| 2024-08-09 | -8.27 |
| 2024-08-08 | -8.29 |
| 2024-08-07 | -8.49 |
| 2024-08-06 | -8.49 |
| 2024-08-05 | -10.80 |
| 2024-08-02 | -10.87 |
| 2024-08-01 | -11.38 |
| 2024-07-31 | -11.49 |
| 2024-07-30 | -11.42 |
| 2024-07-29 | -11.49 |
| 2024-07-26 | -11.67 |
| 2024-07-25 | -11.62 |
| 2024-07-24 | -11.34 |
| 2024-07-23 | -11.45 |
| 2024-07-22 | -11.66 |
| 2024-07-19 | -10.78 |
| 2024-07-18 | -10.92 |
| 2024-07-17 | -11.20 |
| 2024-07-16 | -11.33 |
| 2024-07-15 | -11.17 |
| 2024-07-12 | -10.51 |
| 2024-07-11 | -10.46 |
| 2024-07-10 | -9.79 |
| 2024-07-09 | -9.92 |
| 2024-07-08 | -9.82 |
| 2024-07-05 | -9.71 |
| 2024-07-03 | -9.38 |
| 2024-07-02 | -9.13 |
| 2024-07-01 | -9.40 |
| 2024-06-28 | -9.34 |
| 2024-06-27 | -9.15 |